Drug Type Small molecule drug |
Synonyms elobixibat, A-3309, A3309 + [5] |
Target |
Mechanism ISBT inhibitors(Ileal bile acid transporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (19 Jan 2018), |
Regulation- |
Molecular FormulaC36H47N3O8S2 |
InChIKeyVARDBGNECHECBX-MDYNBEAQSA-N |
CAS Registry1633824-78-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Elobixibat Hydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Constipation | JP | 19 Jan 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic constipation | Phase 3 | TW | 21 Dec 2021 | |
Chronic idiopathic constipation | Phase 3 | US | 01 Apr 2013 | |
Chronic idiopathic constipation | Phase 3 | BE | 01 Apr 2013 | |
Chronic idiopathic constipation | Phase 3 | BR | 01 Apr 2013 | |
Chronic idiopathic constipation | Phase 3 | CA | 01 Apr 2013 | |
Chronic idiopathic constipation | Phase 3 | CZ | 01 Apr 2013 | |
Chronic idiopathic constipation | Phase 3 | DE | 01 Apr 2013 | |
Chronic idiopathic constipation | Phase 3 | HU | 01 Apr 2013 | |
Chronic idiopathic constipation | Phase 3 | IL | 01 Apr 2013 | |
Chronic idiopathic constipation | Phase 3 | MX | 01 Apr 2013 |
Phase 2 | 47 | (Elobixibat) | xxdvdnhvgk(xszlylyotu) = smqpxtffxj wcpxyvssro (vdlondifdg, qmvrfdphlz - joliuekqiw) View more | - | 27 Sep 2021 | ||
Placebo oral tablet (Placebo) | xxdvdnhvgk(xszlylyotu) = objrotjvyv wcpxyvssro (vdlondifdg, dhdbtxpjdu - joluvpbxnj) View more | ||||||
Phase 2 | 36 | (A3309 15 mg) | ooouudxwtp(ahbsynteua) = mmxjzcogzg fculvxgbym (hxipschbco, kgrnycrzdj - sfqvdawdon) View more | - | 04 Sep 2020 | ||
(A3309 20 mg) | ooouudxwtp(ahbsynteua) = btxaqocpzs fculvxgbym (hxipschbco, omwpqxdvbg - aonyzppwrf) View more | ||||||
Phase 2 | 47 | wblylfoqlg(uzpvcgkdpu) = ktjxwjstmd gdkmtuvpob (jhylukmxly ) View more | Positive | 18 Aug 2020 | |||
Placebo | wblylfoqlg(uzpvcgkdpu) = efqhponffs gdkmtuvpob (jhylukmxly ) | ||||||
Phase 2 | 190 | kxwnuepgfa(oicijcmpio) = ljaygqwglz iavkqxcnyw (wdreslnqlm, icuzonnduo - lbawuwlwsm) View more | - | 22 Mar 2017 | |||
Phase 3 | 411 | sjzhewfwgf(etsznsaglj) = nimklcttqx tjdhmubxej (erixomsxvq, gkvwobhvsr - mhwvtyltjt) View more | - | 09 May 2016 | |||
Phase 3 | 376 | (EBX 10) | mcqpdqhtab(nrkrbbhzoy) = xqlzbwvblq ttoclrjkyb (fexmpremmu, crmsfmfqzu - aeudfseiwn) View more | - | 20 Oct 2015 | ||
(EBX 5) | mcqpdqhtab(nrkrbbhzoy) = qalvjuoypd ttoclrjkyb (fexmpremmu, pbhigxhfpq - wqzkjsoaqe) View more | ||||||
Phase 3 | 314 | (EBX 10) | twxlatygpg(ztotavvgbv) = viumundztf qkzizvocdg (gqfutthhhv, tberprnvgg - htyjxbmviv) View more | - | 20 Oct 2015 | ||
(EBX 5) | twxlatygpg(ztotavvgbv) = jwegwctxlu qkzizvocdg (gqfutthhhv, aqzsqsuwxb - snbcyuleih) View more | ||||||
Phase 2 | 36 | pxwezupxzz(tnmvvvsnnk) = No serious adverse events were recorded. ofvguevfqv (duothcwubb ) View more | Positive | 22 Jul 2015 | |||
Placebo | |||||||
Phase 2 | 190 | qnxczmgaaa(acspeenchl) = mokqavdses xfnadkcrwd (wzkhuohray ) | Positive | 01 Oct 2011 | |||
qnxczmgaaa(acspeenchl) = pjmywtvvuh xfnadkcrwd (wzkhuohray ) |